Fundraising Fox
🦊/People
Sign in

Vincent Lepreux

Investor

Investment Director, Debiopharm Innovation Fund S.A. at Debiopharm Innovation Fund · Board director at Strategikon Pharma

Lausanne Metropolitan Area

Find your path to Vincent

198 people in our graph share verified history with Vincent — schools, employers, funds. One of them is your warm intro.

Henri DeshaysunlockedVincent: together at Université Paris Dauphine - PSL (2000–2002)
×5Vincent: together at Université Paris Dauphine - PSL
Vincent: together at Eight Advisory
×5Vincent: together at University of Westminster

About

Vincent Lepreux is an Investment Director at the Debiopharm Innovation Fund, the venture capital fund of biopharma company Debiopharm, where he sources, evaluates, and invests in startups focused on oncology and the digital transformation of pharmaceutical R&D, and serves on the boards of several portfolio companies. He has 14 years of combined experience in financial advisory, M&A, and corporate finance across multiple sectors and geographies. Lepreux holds a Master's degree in Corporate Finance and Financial Engineering from Université Paris Dauphine and venture capital certifications from Wharton and IE Business Schools, and is fluent in English and French.

Contact· self-published, not guessed

Board director at Strategikon Pharma

Intro paths

→

In turn, Vincent can intro founders to Strategikon Pharma's investors below.

Strategikon Pharma's investors · 9

Band of AngelsSilicon Valley · since 2021Bascom VenturesBoston · since 2021Debiopharm Innovation FundLausanne · $1M – $5M checksDecathlon Capital PartnersPalo AltoGolden SeedsFlushing · $250K – $2M checks · since 2021HearstLabNew York · $500K – $1M checksOsage Venture PartnersBala Cynwyd · $500K – $3M checks · since 2021Tech Coast AngelsSouthern California · $5K – $50K checks · since 2021WingPalo Alto · $200K – $20M checks · since 2021

Co-founders at Strategikon Pharma

ACAnca Copaescu
Anca CopaescuFounder
MD
Mark Di IanniExecutive Officer, Director, Promoter

Experience

  1. DebiopharmInvestment Director - Debiopharm Innovation Fundcurrent2019 — presentLausanne Area, Switzerland
  2. iktosBoard Observercurrent2024 — presentParis, Île-de-France, France
  3. StrategikonBoard Membercurrent2023 — presentSan Francisco, California, United States
  4. WhiteLab GenomicsBoard Membercurrent2023 — presentParis, Île-de-France, France
  5. Altis LabsBoard Membercurrent2023 — presentToronto, Ontario, Canada
  6. InovexusPartnercurrent2023 — presentGreater Paris Metropolitan Region
  7. YonalinkBoard Membercurrent2022 — presentBoston, Massachusetts, United States
  8. OncomfortBoard Member2020 — 2023Brussels Region, Belgium
  9. FläktGroupGroup Finance Director2015 — 2019Geneva Area, Switzerland
  10. Eight AdvisorySenior Manager - M&A Transaction Services2013 — 2015Paris Area, France
  11. Deloitte France & UKManager - Financial Advisory2007 — 2013Paris, France and London, United Kingdom
  12. Deloitte France & UKSenior Associate - Audit2005 — 2007Paris Area, France

Skills & more

Microsoft Excel2Microsoft PowerPoint1Group Financial Reporting4Financial Leadership4Originating6Banking2Business1M&A analysisM&A NegotiationsPrivate Equity FirmsValue CreationGrowth Investing
+12 moreHealthcareP&L ManagementGrowth StrategiesGrowth CapitalDealsStakeholder ManagementPresentationsLife SciencesInvestment AnalysisInterpersonal SkillsInterpersonal CommunicationOpen Mind

Languages English · French · German

  • Startup Valuation Methods — Duke University
  • Generative AI for Everyone — DeepLearning.AI
  • Agentic AI and AI Agents: A Primer for Leaders — Vanderbilt University
  • "The Secondaries Market: Key Insights, Strategies, and Applications" — EUVC
  • Artificial Intelligence in Healthcare: Fundamentals and Applications — MIT xPRO
  • Artificial Intelligence in Healthcare: Fundamentals and Applications — MIT xPRO
  • Fund Modelling in VC: Portfolio Construction & Decomposition — EUVC
  • Fund Modelling in VC: Assumption Sheet Construction — EUVC
  • Skills of Negotiation for the Deal Team — UK Private Capital
  • Advanced Venture Capital — IE Business School Executive Education

From Vincent's professional profile.

Colleagues at Debiopharm Innovation Fund

Angela Zubel
Chief Development Officer, Research & Development at Debiopharm Innovation Fund
Bertrand Ducrey
Chief Executive Officer, Debiopharm International & Senior Vice-Chairman, Debiopharm at Debiopharm Innovation Fund
Cedric Odje
Investment Associate at Debiopharm Innovation Fund
Chris Thomas
Director, Investments at Wollemi Capital
David Shin
Investor at Dash Fund
Dawid Książczak
Chief Legal Officer at McWin Capital Partners
Frédéric Lévy
Chief Scientific Officer, Search & Evaluation and Scientific Innovation at Debiopharm Innovation Fund
Kavita Patel
Principal at Muus Climate Partners

Frequently asked questions

Who is Vincent Lepreux?
Vincent Lepreux is an Investment Director at the Debiopharm Innovation Fund, the venture capital fund of biopharma company Debiopharm, where he sources, evaluates, and invests in startups focused on oncology and the digital transformation of pharmaceutical R&D, and serves on the boards of several portfolio companies. He has 14 years of combined experience in financial advisory, M&A, and corporate finance across multiple sectors and geographies. Lepreux holds a Master's degree in Corporate Finance and Financial Engineering from Université Paris Dauphine and venture capital certifications from Wharton and IE Business Schools, and is fluent in English and French.
Where does Vincent Lepreux work?
Vincent Lepreux is Investment Director, Debiopharm Innovation Fund S.A. at Debiopharm Innovation Fund and Board director at Strategikon Pharma.
Where did Vincent Lepreux go to school?
Vincent Lepreux studied at Université Paris Dauphine - PSL (Master's degree, Corporate Finance and Financial Engineering (DESS 225)); Université Paris Dauphine - PSL (4-year degree (Maîtrise de Sciences de Gestion), Business/Management); University of Westminster (Bachelor's degree (exchange programme), Business Administration and Management).

Same school

Shared employers